Potential of Biodegradable Stents in Congenital Heart Disease

被引：0
作者：
Naoyuki Hatayama [1 ]
Tatsuya Watanabe [2 ]
Satoshi Yuhara [1 ]
Benjamin Blais [1 ]
Aimee K. Armstrong [5 ]
Toshiharu Shinoka [6 ]
机构：
[1] Center for Regenerative Medicine, The Abigail Wexner Research Institute, Nationwide Children’s Hospital, Columbus, OH
[2] Department of Anatomy, Aichi Medical University, Aichi, Nagakute
[3] Department of Cardiothoracic Surgery, The Heart Center, Nationwide Children’s Hospital, Columbus, OH
[4] Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH
[5] The Heart Center, Nationwide Children’s Hospital, Columbus, OH
[6] Department of Pediatrics, The Ohio State University, Columbus, OH
来源：
Biomedical Materials & Devices | 2025年 / 3卷 / 1期
关键词：
Biodegradable metal stent; Bioresorbable polymer stent; Bioresorbable scaffold; Congenital heart disease;
D O I：
10.1007/s44174-024-00200-5
中图分类号：
学科分类号：
摘要：
In the USA, approximately 40,000 newborns are diagnosed with congenital heart disease (CHD) annually, with about 1 in 4 of those having critical congenital heart disease requiring surgical or transcatheter intervention in the first year of life. Transcatheter interventions have become the first choice of treatment for certain indications in infancy and early childhood. Since the 1990s, stent placement has been increasingly used as a less invasive alternative to open-heart surgery for CHD treatment, but few stents have been developed specifically for use in infants and growing children. It is common to use adult stents as off-label for pediatric patients, but this is often limited by patient size and stent expansion potential. Currently, nearly all commercially available stents are made of metal and designed for permanent implantation in the vasculature, although bioresorbable polymers and biodegradable metals that allow the stent scaffold to degrade are attracting attention. This technology would allow for acute treatment of lesions in infants and small children without necessarily committing them to multiple future procedures to dilate or surgically open the stent as they grow. Because there are no bioresorbable stents that can be reliably used in pediatric patients with CHD at present, the search for the clinically useful bioresorbable stent platforms continues. This review discusses the potential of bioresorbable stents in the field of congenital heart disease, considering the current status of bioresorbable stents used in clinical settings. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
引用
收藏
页码：349 / 366
页数：17
相关论文
共 137 条
  • [1] Hoffman J.I.E., Kaplan S., The incidence of congenital heart disease, J. Am. Coll. Cardiol, 39, (2002)
  • [2] Reller M.D., Strickland M.J., Riehle-Colarusso T., Mahle W.T., Correa A., Prevalence of congenital heart defects in metropolitan Atlanta, 1998–2005, J. Pediatr, 153, (2008)
  • [3] Peters B., Ewert P., Berger F., The role of stents in the treatment of congenital heart disease: current status and future perspectives, Ann. Pediatr. Cardiol, 2, (2009)
  • [4] Ing F., Stents: what’s available to the pediatric interventional cardiologist?, Catheter. Cardiovasc. Interv, 57, (2002)
  • [5] Hascoet S., Baruteau A., Jalal Z., Mauri L., Acar P., Elbaz M., Boudjemline Y., Fraisse A., Stents in paediatric and adult congenital interventional cardiac catheterization, Arch. Cardiovasc. Dis, 107, (2014)
  • [6] Serruys P.W., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G., Emanuelsson H., Marco J., Legrand V., Materne P., A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease Benestent Study Group, N. Engl. J. Med, 331, (1994)
  • [7] Hoffmann R., Mintz G.S., Dussaillant G.R., Popma J.J., Pichard A.D., Satler L.F., Kent K.M., Griffin J., Leon M.B., Patterns and mechanisms of in-stent restenosis, Circulation, 94, (1996)
  • [8] Claessen B.E., Henriques J.P.S., Jaffer F.A., Mehran R., Piek J.J., Dangas G.D., Stent thrombosis: a clinical perspective, JACC Cardiovasc. Interv, 7, (2014)
  • [9] Morice M.-C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnar F., Falotico R., Randomized study with the Sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions: a randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization, N. Engl. J. Med, 346, (2002)
  • [10] Stone G.W., Ellis S.G., Cannon L., Mann J.T., Greenberg J.D., Spriggs D., O'Shaughnessy C.D., DeMaio S., Hall P., Popma J.J., Koglin J., Russell M.E., TAXUS V Investigators: Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial, JAMA, 294, (2005)
12345678910